Summary of Study ST000248
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000200. The data can be accessed directly via it's Project DOI: 10.21228/M8JC79 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST000248 |
Study Title | Metabolic heterogeneity in Glioblastoma |
Study Type | Multiple patient-derived cell lines screening |
Study Summary | 2 cell populations [slow and fast-cycling cells] were isolated from 3 different patient-derived glioblastoma stem cell lines [L0, L1, L2]. |
Institute | University of Florida |
Department | SECIM |
Laboratory | Garrett Lab |
Last Name | Deleyrolle |
First Name | Loic |
Address | R3-226 Academic Research Building, Department of Biochemistry and Molecular Biology, PO Box 100245, Gainesville, FL 32610-0245 |
l.deleyrolle@gmail.com | |
Submit Date | 2015-03-24 |
Num Groups | 2 |
Total Subjects | 6 |
Study Comments | Line names: L0, L1 & L2. Subpopulation names: slow-cycling cells [S], fast-cycling cell [F]. Sample list: L0-S, L0-F, L1-S, L1-F, L2-S, L2-F |
Raw Data Available | Yes |
Raw Data File Type(s) | mzXML |
Uploaded File Size | 1 GB |
Analysis Type Detail | LC-MS |
Release Date | 2016-09-23 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR000200 |
Project DOI: | doi: 10.21228/M8JC79 |
Project Title: | Metabolic heterogeneity in Glioblastoma |
Project Summary: | Glioblastoma (GB) is the most common and complex primary brain tumor in adults and has a dismal prognosis, which is attributed largely to the extreme heterogeneity in the cells that make up the cancer and the continual molecular, genetic and metabolic adaptations driving tumor initiation, propagation and resistance to conventional treatments. The most important clinical target to prevent these mechanisms of initiation, propagation and disease recurrence may be a subset of tumor cells, cancer stem cells. Hence, identifying targetable key features of this population is of great interest for the elaboration of strategies to prevent disease initiation and propagation as well as recurrence post treatments. In response to i) the limited success to treat GB that remains universally fatal, ii) the evidences pointing to tumor heterogeneity as the greatest obstacle to achieve therapeutic efficacy and iii) the increasing understanding and importance of bioenergetics in tumor biology and the critical need to integrate metabolism into treatment paradigms, we propose a new model residing in the unique and unprecedented hypothesis of an association between GB management, a distinct slow-cycling cancer stem cell subpopulation and metabolic targeting. |
Institute: | University of Florida |
Department: | McKnight Brain Institute, Neurosurgery |
Last Name: | Deleyrolle |
First Name: | Loic |
Address: | #N/A |
Email: | l.deleyrolle@gmail.com |
Phone: | 352-682-1961 |
Subject:
Subject ID: | SU000268 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Species Group: | Mammals |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Cell population |
---|---|---|
SA011378 | L1-fast | Fast-cycling cells |
SA011379 | L2-fast | Fast-cycling cells |
SA011380 | L0-fast | Fast-cycling cells |
SA011381 | L2-slow | Slow-cyling cells |
SA011382 | L1-slow | Slow-cyling cells |
SA011383 | L0-slow | Slow-cyling cells |
Showing results 1 to 6 of 6 |
Collection:
Collection ID: | CO000259 |
Collection Summary: | - |
Collection Protocol Filename: | Deleyrolle_Collection.txt |
Sample Type: | Cells |
Treatment:
Treatment ID: | TR000279 |
Treatment Protocol Filename: | Deleyrolle_Treatment_File.txt |
Sample Preparation:
Sampleprep ID: | SP000273 |
Sampleprep Summary: | - |
Sampleprep Protocol Filename: | Metabolomics_LCMSProtocol.pdf |
Sampleprep Protocol Comments: | Appendix A - Internal Standard Prep GLCMS.pdf |
Combined analysis:
Analysis ID | AN000391 | AN000392 |
---|---|---|
Analysis type | MS | MS |
Chromatography type | Reversed phase | Reversed phase |
Chromatography system | Thermo Dionex Ultimate 3000 | Thermo Dionex Ultimate 3000 |
Column | ACE Excel 2 C18-PFP (100 x 2.1mm, 2um) | ACE Excel 2 C18-PFP (100 x 2.1mm, 2um) |
MS Type | ESI | ESI |
MS instrument type | Orbitrap | Orbitrap |
MS instrument name | Thermo Q Exactive Orbitrap | Thermo Q Exactive Orbitrap |
Ion Mode | POSITIVE | NEGATIVE |
Units | peak height | peak height |
Chromatography:
Chromatography ID: | CH000278 |
Methods Filename: | Metabolomics_LCMSProtocol.pdf |
Instrument Name: | Thermo Dionex Ultimate 3000 |
Column Name: | ACE Excel 2 C18-PFP (100 x 2.1mm, 2um) |
Flow Rate: | 0.350mL/min-0.600mL/min |
Solvent A: | 100% water; 0.1% formic acid |
Solvent B: | 100% acetonitrile |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS000335 |
Analysis ID: | AN000391 |
Instrument Name: | Thermo Q Exactive Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
Ion Mode: | POSITIVE |
MS ID: | MS000336 |
Analysis ID: | AN000392 |
Instrument Name: | Thermo Q Exactive Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
Ion Mode: | NEGATIVE |